230 related articles for article (PubMed ID: 20131938)
1. End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Vernerová Z; Kujal P; Kramer HJ; Bäcker A; Cervenka L; Vaneckova I
Physiol Res; 2009; 58 Suppl 2():S69-S78. PubMed ID: 20131938
[TBL] [Abstract][Full Text] [Related]
2. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Vanecková I; Kramer HJ; Bäcker A; Schejbalová S; Vernerová Z; Eis V; Opocenský M; Dvorák P; Cervenka L
Vascul Pharmacol; 2006 Sep; 45(3):163-70. PubMed ID: 16807127
[TBL] [Abstract][Full Text] [Related]
3. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats.
Vernerová Z; Kramer HJ; Bäcker A; Cervenka L; Opocenský M; Husková Z; Vanourková Z; Eis V; Chábová VC; Tesar V; Malý J; Vanecková I
Vascul Pharmacol; 2008; 48(4-6):165-73. PubMed ID: 18372220
[TBL] [Abstract][Full Text] [Related]
4. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.
Opocenský M; Kramer HJ; Bäcker A; Vernerová Z; Eis V; Cervenka L; Certíková Chábová V; Tesar V; Vanecková I
Hypertension; 2006 Nov; 48(5):965-71. PubMed ID: 17015777
[TBL] [Abstract][Full Text] [Related]
5. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Vanêcková I; Kramer HJ; Bäcker A; Vernerová Z; Opocensky M; Cervenka L
Hypertension; 2005 Oct; 46(4):969-74. PubMed ID: 16157796
[TBL] [Abstract][Full Text] [Related]
6. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats.
Dvorák P; Kramer HJ; Bäcker A; Malý J; Kopkan L; Vanecková I; Vernerová Z; Opocenský M; Tesar V; Bader M; Ganten D; Janda J; Cervenka L
Kidney Blood Press Res; 2004; 27(4):248-58. PubMed ID: 15286437
[TBL] [Abstract][Full Text] [Related]
7. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Rothermund L; Kossmehl P; Neumayer HH; Paul M; Kreutz R
J Hypertens; 2003 Dec; 21(12):2389-97. PubMed ID: 14654760
[TBL] [Abstract][Full Text] [Related]
8. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
Vanourková Z; Kramer HJ; Erbanová M; Bäcker A; Cervenka L; Husková Z; Chábová VC; Tesar V; Dvorák P; Malý J; Vanecková I
Vascul Pharmacol; 2009; 50(5-6):194-9. PubMed ID: 19563737
[TBL] [Abstract][Full Text] [Related]
9. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats.
Opocenský M; Dvorák P; Malý J; Kramer HJ; Bäcker A; Kopkan L; Vernerová Z; Tesar V; Zima T; Bader M; Ganten D; Janda J; Vanecková I
Physiol Res; 2004; 53(6):581-93. PubMed ID: 15588125
[TBL] [Abstract][Full Text] [Related]
10. [Morphological characteristic of renal injury in hypertensive rat strain transgenic for the mouse Ren-2 renin gene (TGR [mRen2] 27].
Vernerová Z
Cesk Fysiol; 2007; 56(2):79-84. PubMed ID: 17691484
[TBL] [Abstract][Full Text] [Related]
11. Distinct effects of bosentan on NO-dependent vasodilation and calcium influx in heterozygous Ren-2 transgenic rats on high-salt diet.
Vaněčková I; Hojná S; Kadlecová M; Kompanowska-Jezierska E; Zicha J
Physiol Res; 2019 Oct; 68(5):717-725. PubMed ID: 31424254
[TBL] [Abstract][Full Text] [Related]
12. Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet.
Vaněčková I; Dobešová Z; Kuneš J; Vernerová Z; Zicha J
J Hypertens; 2015 Jan; 33(1):161-9. PubMed ID: 25255392
[TBL] [Abstract][Full Text] [Related]
13. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Lee TM; Chen CC; Lin MS; Chang NC
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1871-9. PubMed ID: 18281380
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system blockade alone or combined with ET
Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
[TBL] [Abstract][Full Text] [Related]
15. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
[TBL] [Abstract][Full Text] [Related]
16. Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade.
Vaněčková I; Řezáčová L; Kuneš J; Zicha J
Life Sci; 2016 Aug; 159():127-134. PubMed ID: 26775568
[TBL] [Abstract][Full Text] [Related]
17. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats.
Elmarakby AA; Dabbs Loomis E; Pollock JS; Pollock DM
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S7-10. PubMed ID: 15838363
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Vaněčková I; Kujal P; Husková Z; Vaňourková Z; Vernerová Z; Certíková Chábová V; Skaroupková P; Kramer HJ; Tesař V; Červenka L
Kidney Blood Press Res; 2012; 35(5):382-92. PubMed ID: 22487948
[TBL] [Abstract][Full Text] [Related]
19. Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension.
Kala P; Gawrys O; Miklovič M; Vaňourková Z; Škaroupková P; Jíchová Š; Sadowski J; Kompanowska-Jezierska E; Walkowska A; Veselka J; Táborský M; Maxová H; Vaněčková I; Červenka L
J Hypertens; 2023 Jan; 41(1):99-114. PubMed ID: 36204993
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
